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Background: Identification of unknown chemical entities is a major challenge in 30 
metabolomics. To address this challenge, we developed a comprehensive targeted 31 
profiling strategy, combining three complementary liquid chromatography (LC) 32 
quadrupole time-of-flight mass spectrometry (QTOF-MS) techniques and in-house 33 
accurate mass retention time (AMRT) databases established from commercial 34 
standards. This strategy was used to evaluate the effect of nitisinone on the urinary 35 
metabolome of patients and mice with alkaptonuria (AKU). Because hypertyrosinemia 36 
is a known consequence of nitisinone therapy, we investigated the wider metabolic 37 
consequences beyond hypertyrosinemia. 38 
Methods: 619 standards (molecular weight 45-1354 Da) covering a range of primary 39 
metabolic pathways were analyzed using three LC methods, two reversed phase and 40 
one normal phase, coupled to QTOF-MS. Separate AMRT databases were generated 41 
for the three methods, comprising chemical name, formula, theoretical accurate mass 42 
and measured retention time. Databases were used to identify chemical entities 43 
acquired from non-targeted analysis of AKU urine; match window theoretical accurate 44 
mass ±10 ppm and retention time ±0.3 min.  45 
Results: Application of the AMRT databases to data acquired from analysis of urine 46 
from 25 patients with AKU (pre-treatment and after 3, 12 and 24 mo on nitisinone) and 47 
18 HGD-/- mice (pre-treatment and after one week on nitisinone) revealed 31 48 
previously unreported statistically significant changes in metabolite patterns and 49 
abundance, indicating alterations to tyrosine, tryptophan and purine metabolism post-50 
nitisinone. 51 
4 
Conclusions: The comprehensive targeted profiling strategy described here has the 52 
potential of enabling discovery of novel pathways associated with pathogenesis and 53 
treatment of AKU. 54 
  55 
5 
Metabolic profiling has potential to advance knowledge of disease beyond established 56 
biochemical pathways and will play a major role in precision medicine (1-5). However, 57 
metabolite identification is a major challenge in untargeted profiling studies using mass 58 
spectrometry (MS) (6,7) since they generate many chemical signals representing 59 
‘unknowns’. To address this challenge, we generated three accurate mass/retention 60 
time (AMRT) databases from 619 metabolite standards using liquid chromatography-61 
quadrupole time-of-flight-mass spectrometry (LC-QTOF-MS). We applied this strategy 62 
to the inborn error of metabolism alkaptonuria (AKU, OMIM 203500). In AKU, bi-allelic 63 
mutations in the homogentisate 1,2-dioxygenase (HGD) gene result in a lack of 64 
homogentisate 1,2-dioxygenase (HGD, E.C.1.12.11.5) (8), leading to increased 65 
homogentisic acid (HGA), a metabolite of tyrosine catabolism (Fig. 1). HGA 66 
accumulates in connective tissue, particularly cartilage, where it is deposited as a dark 67 
pigment, a process termed ochronosis. Ochronosis underlies a range of clinical 68 
features in AKU, the most debilitating of which is severe, early-onset osteoarthropathy 69 
that alters the physico-mechanical properties of cartilage (9,10). 70 
Nitisinone has emerged as a promising therapeutic agent in AKU because it reduces 71 
circulating HGA concentrations (11–15) by reversibly inhibiting hydroxyphenylpyruvic 72 
acid dioxygenase (E.C. 1.13.11.27). Nitisinone completely inhibits ochronosis in an 73 
HGD-/- mouse model of AKU (16). Although not currently licensed for AKU, nitisinone 74 
is being used to treat patients attending the National Alkaptonuria Centre (NAC) in the 75 
UK. One of the major metabolic consequences of nitisinone is hypertyrosinaemia 76 
(11,13–15,17–21) (Fig. 1). The objective of our study was to apply the developed 77 
profiling strategy to urine from patients with AKU and HGD-/- mice to understand the 78 
wider metabolic consequences of nitisinone treatment. 79 
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 80 
Materials and Methods 81 
Metabolite standards library preparation 82 
619 standards (IROA Technology MS metabolite library of standards; molecular 83 
weight 45-1354 Da) were from Sigma-Aldrich (UK) in seven deepwell plates. Each 84 
compound was present at 5 µg/well (>95% purity). Plates were stored at -80°C. The 85 
standards covered a broad range of primary and intermediary metabolism, including 86 
the following compound classes: carboxylic acids, amino acids, biogenic amines, 87 
polyamines, nucleotides, coenzymes, vitamins, carbohydrates, fatty acids, lipids, 88 
steroids and hormones (Supplemental Files 1 and 2).  89 
Prior to analysis, plates were thawed at ambient temperature (18˚C) and compounds 90 
reconstituted in 15 µL methanol (LC/MS grade, Sigma-Aldrich) followed by 285 µL 91 
deionized water (DIRECT-Q 3UV Millipore water purification system). Plates 1-5 were 92 
left to stand for 1 h following addition of water and methanol. Plates 6 and 7 (primarily 93 
non-polar compounds) were left to stand for 2 h at room temperature following addition 94 
of methanol to ensure solubilization; water was then added. Plates were agitated on a 95 
plate shaker (MTS 2/4m IKA, Germany) at 600 rpm for 10 min. Compounds were 96 
pooled across rows of each plate (12 wells/row). 20 µL was removed from each well 97 
and pooled into one well (12 compounds analyzed per injection). Fifty-six injections 98 
were performed in positive and negative polarity across all plates (112 injections for 99 
each LC-QTOF-MS method; Supplemental Fig. 1). The total volume of each pool was 100 
240 µL with each compound at 14 mg/dL (1-31 µmol/L). 101 
  102 
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Evaluation of LC-QTOF-MS strategy and effect of nitisinone on the metabolome using 103 
AKU urine 104 
24 h urine was obtained from 25 patients with AKU attending the NAC (12 male, 105 
mean(±SD) age 51±15 y). Samples were collected before nitisinone then at 3 (2 mg 106 
every other day), 12 and 24 (2 mg daily) mo on nitisinone and stored at -80°C. 107 
Samples were diluted 1:3 with deionized water and stored at -80°C as three separate 108 
aliquots for analysis by methods 1-3. Metabolomic analysis was part of the diagnostic 109 
service to patients being seen at the NAC and with approval from the Royal Liverpool 110 
and Broadgreen University Hospital Trusts Audit Committee (audit no. ACO3836). 111 
Mouse urine was from 18 (9 male, mean age 27±12 wk) HGD-/- BALB/c mice (16) bred 112 
from laboratory stocks at the University of Liverpool. Samples were obtained on a 113 
single-collection basis before treatment then after 1 wk on nitisinone, administered in 114 
all drinking water (0.4 mg/dL), supplied ad libitum. Mouse urine was collected onto 115 
cling film, pipetted into sample tubes and stored at -80°C. Analysis was performed 116 
following dilution of 1:9 with deionized water. Mouse breeding and dosing was 117 
authorized under the Animals (Scientific Procedures) Act, UK. 118 
Samples were pooled for quality assurance in profiling experiments. For each 119 
sampling time point, a representative pool was created by pooling 20 µL of each 120 
individual urine sample. An additional overall pool was created separately for human 121 
and mouse experiments by pooling equal proportions of the pooled urine groups 122 
detailed above. Pooled human and mouse samples were stored and treated as above 123 
prior to analysis. 124 
  125 
8 
Analytical conditions 126 
Chemicals 127 
Water for mobiles phases was purified as above. Methanol, acetonitrile, isopropanol 128 
(Sigma-Aldrich), formic acid (Biosolve, Netherlands) and ammonium formate (Fisher 129 
Scientific, Germany) were LC/MS grade. 130 
Equipment 131 
Sample analysis was performed on an Agilent 1290 Infinity LC coupled to an Agilent 132 
6550 QTOF-MS equipped with a dual AJS electrospray ionization source (Agilent, 133 
UK). 134 
Chromatographic conditions 135 
Three chromatographic methods were designed to separate different compound 136 
classes. Method 1: non-polar compounds. Method 2: a range of polar/non-polar 137 
compounds. Method 3: polar compounds. Metabolite standards were analyzed using 138 
all three LC-QTOF-MS techniques.  139 
Method 1 140 
A Zorbax Eclipse Plus C18 column (2.1x100 mm, 1.8 µm, Agilent) was maintained at 141 
60°C (flow rate 0.4 mL/min). Mobile phases were (A) water and (B) methanol both 142 
containing 31.6 mg/dL ammonium formate and 0.1% formic acid. The elution gradient 143 
started at 5% B at 0-1 min increasing linearly to 100% by 12 min, held at 100% B until 144 
14 min, returning to 95% A for 5 min.  145 
Method 2 146 
9 
Method 2 employed the same conditions and elution gradient as method 1, but with 147 
an Atlantis dC18 column (3x100 mm, 3 µm, Waters, UK). 148 
Method 3 149 
A BEH amide column (3x150 mm, 1.7 µm, Waters) was maintained at 40°C (flow rate 150 
0.6 mL/min). Mobile phases were (A) water and (B) acetonitrile (both containing 0.1% 151 
formic acid). The elution gradient started at 99% B decreasing linearly to 30% from 1-152 
12 min, held at 30% B until 12.6 min, returning to 99% B for 3.4 min. 153 
Sample injection volume was 1 µL for metabolite standards and human urine, and 2 154 
µL for mouse urine. The autosampler was maintained at 4°C and the needle was 155 
washed with a solution of water:methanol:isopropanol (45:45:10 v/v) between 156 
injections. 157 
  158 
Design of urine metabolic profiling experiments 159 
Human and mouse urine was analyzed separately. Human samples were analyzed 160 
batch-wise using all 3 methods, negative followed by positive polarity. Mouse samples 161 
were analyzed by method 2 only due to limited sample volumes, in one batch 162 
comprising both polarities.  163 
The analytical sequence of each profiling batch was designed according to published 164 
guidance (22). Each run commenced with 20 replicate injections of the overall pooled 165 
sample to condition the system. The order of individual samples was randomized 166 
computationally. Pooled samples were interspersed throughout the analytical 167 
sequence, every 10th injection. Injections of each sample group pool and the overall 168 
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pooled sample were also placed at the start (post-conditioning) and end of each 169 
analytical sequence. 170 
 171 
Data acquisition and processing 172 
Data acquisition and processing were performed using the MassHunter suite (Agilent). 173 
Data were acquired with Data Acquisition (build 06.00). Metabolite standards and 174 
urine samples were analyzed in both polarities, mass range 50-1700 (Supplemental 175 
File 3). Quality checks and processing of raw data were performed with Qualitative 176 
Analysis (build 07.00). Extracted ion chromatograms of reference masses were 177 
performed to check mass accuracy remained <5 ppm throughout the run. Binary pump 178 
pressure curves for injections across each analytical sequence were overlaid to check 179 
chromatographic reproducibility. 180 
Compound signals were extracted from the standards data in Qualitative Analysis 181 
(build 07.00) by molecular formula using the ‘find by formula’ algorithm; mass window 182 
of theoretical accurate mass (calculated from molecular formula) ±5 ppm. Allowed ion 183 
species were: H+ and Na+ and additionally NH4+ for methods 1 and 2 (positive polarity); 184 
and H- and additionally CHO2- for methods 1 and 2 (negative polarity). Charge state 185 
range was 1-2. Dimers were allowed. Separate AMRT databases were created for 186 
each method using PCDL Manager (build 08.00). Theoretical accurate mass, retention 187 
time (RT), molecular formula and METLIN chemical name were entered into each 188 
AMRT database for compounds that were retained and detected (databases publicly 189 
available via https://figshare.com/collections/_/4378235/0 (23)). 190 
Urine profiling data were mined for signals matching AMRT database compounds 191 
using ‘targeted feature extraction’ (Profinder, build 08.00). Targeted feature extraction 192 
11 
uses the molecular formulae to extract and group spectral signals (i.e. adducts, 193 
multimers and isotopes), corresponding to individual database compounds. Feature 194 
extraction window; theoretical accurate mass ±10 ppm and database RT ±0.3 min. 195 
Allowed ion species were the same as specified above.  196 
  197 
Detection of non-AMRT database compounds in urine  198 
Urine data were also mined using Profinder for compounds not from generated AMRT 199 
databases but of interest for their predicted role in AKU/nitisinone metabolism. These 200 
compounds were associated with a) increased tyrosine: acetyl-L-tyrosine, γ-glutamyl-201 
L-tyrosine and tyramine-sulfate; b) ochronotic pigment: 2,5-dihydroxybenzaldehyde, 202 
hipposudoric acid and norhipposudoric acid; or c) nitisinone metabolism: hydroxy-203 
nitisinone, nitisinone and 2-nitro-4-trifluoromethylbenzoic acid. For non-AMRT 204 
compounds, the same RT (range <0.3 min) was required across samples. Compound 205 
identifications were based on theoretical accurate mass ±10 ppm.  206 
 207 
Data quality control and statistical analyses 208 
Several quality control (QC) filters were applied to AMRT-matched entities from each 209 
profiling batch. First, entities were retained if observed in at least two samples per 210 
experimental group (i.e. sampling time point). Data files were then exported from 211 
Profinder and imported into Mass Profiler Professional (build 14.5). 24 h creatinine 212 
excretions (Roche Diagnostics, Germany) were used as external scalar for individual 213 
human urine samples (average values across each sampling time point used for 214 
pooled samples). Creatinine values were not available for mouse samples; the signal 215 
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identified as creatinine by matched AMRT was used as external scalar for each 216 
sample using the peak area of the 13C [M+H]+ ion (13C because 12C creatinine signal 217 
was saturated) calculated in MassHunter Quantitative analysis (build 06.00). 218 
Entities were then further filtered in Mass Profiler Professional based on data from 219 
pooled samples from each experiment. Entities were retained if observed in 100% of 220 
replicate injections for at least one sample group pool, and with peak area coefficient 221 
of variation (CV) <25% across replicate injections of all sample group pools. 222 
Statistical analyses were performed in Mass Profiler Professional based on peak area. 223 
Human urine profiles were compared at 3, 12 and 24 mo on nitisinone with pre-224 
nitisinone by one-way repeated-measures ANOVA. Mouse urine profiles were 225 
compared pre-nitisinone vs 1 wk on nitisinone by paired t-test. Benjamini-Hochberg 226 
false-discovery rate adjustment was used in all statistical significance testing. Fold 227 
changes (FC’s) were calculated based on raw peak area. Principal component 228 
analyses employing four-component models were also performed on each filtered 229 
dataset.  230 
 231 
Results 232 
Analysis of metabolite standards 233 
Signals representing the chemical formulae for standards in each injection were 234 
extracted from the data by theoretical accurate mass ±5 ppm. Only standards with RT 235 
>0.3 min after the column void volume were considered. 519/619 (83.8%) of the 236 
standards were retained sufficiently to be detected by at least one method. 116/619 237 
(18.7%) and 226/619 (36.5%) of the compounds were retained sufficiently and 238 
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detected by one or two methods only, respectively, demonstrating the utility of 239 
combining data from the three chromatographic methods (Figure 2A). RT, accurate 240 
mass and charge state were entered into an AMRT metabolite database for each 241 
method for matching unknowns against.  242 
Figure 2B-D shows the mass/RT distribution for compounds detected by each method. 243 
Figure 2B-D also highlights differences in selectivity for compounds from three 244 
example compound groups with different chemical properties: carbohydrates, amino 245 
acids and lipids (Supplemental File 4). Method 3 retained and separated highly polar 246 
compounds such as carbohydrates (20/26 detected, RT range 5-9.5 min). In methods 247 
1 and 2, the same carbohydrates were weakly retained; for method 1 all carbohydrates 248 
detected eluted within the initial column void (24/26 detected, RT range 0.58-0.68 min) 249 
and for method 2 all carbohydrates detected eluted close to the initial void (23/26 250 
detected, RT range 1.3-1.4 min). Method 1 showed some evidence of improved 251 
suitability for analysis of lipid-like compounds (11/11 detected, RT range 7.7-13.7 min) 252 
compared to methods 2 (8/11 detected, RT range 9.3-14.3 min) and 3 (7/11 detected, 253 
RT range 1.5-8.3 min), which detected fewer of these compounds within a narrower 254 
RT range overall. All three methods enabled detection of the amino acids, with method 255 
3 appearing to show the most useful chromatographic resolution and retention (19/21 256 
detected, RT range 5.4-8.1 min) compared to methods 1 (21/21 detected, RT range 257 
0.6-2.8 min) and 2 (21/21 detected, RT range 1.0-4.6 min). 258 
  259 
Identification of metabolites in pooled urine by AMRT 260 
Unknown chemical entities were matched against the respective AMRT database 261 
generated for each method: accurate mass ±10 ppm, RT ±0.3 min. For data presented 262 
14 
here, analysis comprised two replicate injections of the overall pooled urine from 263 
patients with AKU from the start and end of each analytical run. Only unknowns 264 
obtained from both injections in positive or negative polarity and with single AMRT 265 
compound matches were retained in this analysis. Additional QC filters were then 266 
applied to ensure reproducibility across the run: CV <25% for peak area and RT 267 
between the two replicate injections. Table 1 summarizes matches retained for each 268 
method. No compounds were filtered out due to RT CV >25%. The maximum RT CV% 269 
change between the replicate injections across all analytical runs (each comprised 270 
205 injections) was 4.1%. 271 
Figure 3A shows that 203 unique compound matches were obtained from urine. 272 
Supplemental File 5 shows the matches obtained by methods 1-3. Fourteen AMRT 273 
matches were obtained by all three methods. An additional 61 AMRT matches were 274 
obtained by two methods, and 128 matches by only one of the methods, further 275 
supporting the increased coverage from the three methods in combination. Figure 3B-276 
D shows the mass/RT distribution of the AMRT matches. 277 
Table 1 and Supplemental Figure 2 show the number of AMRT matches obtained with 278 
narrower AMRT-matching windows. For each method, >50% of matches obtained with 279 
±10 ppm and ±0.3 min post-QC remained with ±5 ppm and ±0.15 min. 280 
 281 
Application of strategy to AKU: effect of nitisinone therapy on the urine metabolome 282 
Figure 4A,B shows the overall study design and a representative example of AMRT 283 
compound signals extracted from the data respectively. Representative principal 284 
components analysis plots (Figure 4C) show clear separation between the AMRT-285 
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matched profiles of urine pre- vs post-nitisinone for human and mouse, showing that 286 
our strategy captured key metabolite changes. 287 
Thirty-five metabolites showed statistically significant changes (p<0.05, FC>2) in 288 
abundance after 3, 12 or 24 mo on nitisinone in humans or 1 wk on nitisinone in mice 289 
(Figure 5). An FC >2 was chosen in order to limit false discovery and focus on clear 290 
changes. In patients with AKU, 13 metabolites increased and 14 decreased. In HGD-291 
/- mice, 12 metabolites increased and 6 decreased. Ten metabolites changed in the 292 
same direction in humans and mice (Figure 5). Together, the majority of these 293 
metabolite changes could be categorized into three main metabolic pathways: those 294 
of tyrosine, tryptophan and purine. 295 
Interestingly, mouse data also showed clear separation by gender (principal 296 
component 1; x-axis Figure 4C). Histamine was the primary driver of this separation 297 
in positive polarity (principal component 1 loading; 0.42), which captured the effect of 298 
gender and explained 43% of the variation in the dataset. Histamine was significantly 299 
increased in female mice (p<0.0001, FC=16).  300 
 301 
Alterations to non-AMRT database compounds post-nitisinone 302 
Data showed alteration (p<0.05, FC>2) to metabolites with a predicted association to 303 
AKU/nitisinone metabolism that were not from AMRT databases (Supplemental Figure 304 
3). 2,5-dihydroxybenzaldehyde, probably associated with ochronotic pigment, was 305 
decreased post-nitisinone. The tyrosine metabolites acetyl-L-tyrosine and γ-glutamyl-306 
L-tyrosine and the nitisinone metabolite hydroxy-nitisinone were increased. These 307 
changes were observed in human and mouse urine.  308 
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  309 
Discussion 310 
We have developed a strategy for comprehensive LC-QTOF-MS profiling with 311 
compound identification by three AMRT databases generated from metabolite 312 
standards. Application of this strategy enabled: a) identification of unknown chemical 313 
entities in complex biological matrix by AMRT; and b) identification of previously 314 
unreported changes to urinary metabolites and metabolic pathways following 315 
nitisinone treatment in AKU.  316 
A limitation of LC-MS compound identification by public databases (24–28) is that data 317 
were acquired using different analytical techniques and parameters. The 318 
Metabolomics Standards Initiative has established levels of metabolite identification 319 
confidence (29,30). Only identification strategies, as reported here, that compared two 320 
or more orthogonal chemical properties (e.g. AMRT) with an authentic standard under 321 
identical analytical conditions achieved the highest identification confidence level. 322 
Identifications by public databases in which data were acquired under different 323 
analytical conditions can only achieve the second level of confidence (‘putative 324 
identification’), even with two matched orthogonal chemical properties. 325 
Combining data from three LC techniques enhanced the number of unique urine 326 
AMRT matches obtained, improving coverage of the metabolome. Methods 1 and 2 327 
showed some similarity in analyte retention (Figure 2B-D). Method 2 was used 328 
because the Atlantis dC18 column was previously shown to chromatographically 329 
resolve metabolites of the tyrosine pathway in patients with AKU (31-32). It also 330 
provided greater overall retention of polar metabolites compared to a standard C18 331 
column due to endcapping of bi-functionally bonded C18 stationary phase. Method 1 332 
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was included here to improve peak capacity owing to the increased theoretical plates 333 
provided by the smaller 2.1 µm column particle size. Moreover, methods 1 and 2 334 
yielded 39 and 57 AMRT matches respectively that were exclusive to each method 335 
(Figure 3A). 336 
The congenital defect that causes AKU directly affects tyrosine catabolism. However, 337 
AKU is multi-systemic (9) and the wider metabolic consequences of the disease and 338 
nitisinone treatment have not been systematically studied. The strategy was applied 339 
to AKU, but given the range of primary and intermediary metabolism covered by the 340 
AMRT compounds, it could be applied to study metabolism in any disease. The data 341 
show that nitisinone alters tyrosine and tryptophan metabolism, and support alteration 342 
to the purine metabolic pathway. The changes observed comprise increased and 343 
decreased concentrations within the same pathways, suggesting that nitisinone has 344 
complex, wide-ranging effects on metabolism. Nitisinone is licensed to treat patients 345 
with hereditary tyrosinaemia type-1 (HT-1, OMIM 276700), another congenital disease 346 
of tyrosine metabolism, and is a promising HGA-reducing agent in AKU. In nitisinone-347 
treated HT-1 and AKU it is established that circulating tyrosine increases markedly 348 
(11,13–15,17–21). Tyrosine is the precursor for catecholamines, thyroid hormones 349 
and melanin (Figure 1), suggesting that increased tyrosine substrate has potential to 350 
dysregulate these pathways. In HT-1 there are concerns that hypertyrosinaemia may 351 
contribute to neurodevelopmental delay (19,33-36). 352 
Application of our profiling strategy identified a number of previously unreported 353 
metabolite changes post-nitisinone. Increased 3-(4-hydroxyphenyl)lactic acid is 354 
probably directly related to elevated tyrosine and/or its clearance in urine. Changes a) 355 
homovanillic acid and the trace amine tyramine and b) L-tryptophan represent further 356 
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alterations to dopamine and tryptophan-serotonin metabolism (respectively) than 357 
those previously reported. L-tryptophan is the precursor for serotonin, and a post-358 
nitisinone increase in the serotonin metabolite 5-hydroxyindoleacetic acid was 359 
previously reported in HT-1 cerebrospinal fluid (37) and AKU urine (20), although not 360 
observed here. Xanthurenic acid and L-kynurenine were increased and decreased 361 
respectively, indicating for the first time that the kynurenine pathway, originating from 362 
tryptophan, is altered by nitisinone. Also, indoxyl sulfate, a metabolite of the 363 
indolepyruvate pathway from tryptophan, was decreased. Alterations to 364 
indolepyruvate metabolism are previously reported in nitisinone-treated AKU plasma; 365 
carboxaldehyde, indole-lactate and indole-pyruvate increased, and in vitro studies 366 
indicated this as a direct consequence of increased 3-(4-hydroxyphenyl)pyruvic acid 367 
(38). This is the first report of alterations to purine metabolism following treatment with 368 
nitisinone. Decreased 3,5-cyclic-AMP and xanthosine were unexpected but replicated 369 
in mice. 370 
The remaining metabolite changes have been previously reported following nitisinone 371 
treatment; decreased HGA and increased tyrosine, acetyl-L-tyrosine, γ-glutamyl-372 
tyrosine, 3-(4-hydroxyphenyl)pyruvic acid and 3-methoxytyramine. Decreased HGA 373 
and increased tyrosine are well-known consequences of nitisinone, and observation 374 
of these changes in each analytical run (tyrosine in positive and HGA in negative 375 
polarity) supports the analysis, data extraction workflow, and validity of the data. 376 
Increased acetyl-L-tyrosine and γ-glutamyl-tyrosine have been previously reported in 377 
nitisinone-treated AKU and were proportional to tyrosine elevation (39). Increased 3-378 
methoxytyramine was previously reported in AKU urine (20); it is a metabolite of 379 
dopamine metabolism and derived from tyrosine via decarboxylation of 380 
dihydroxyphenylalanine to dopamine.  381 
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Ten AMRT-matched metabolite changes were observed in human and mouse: 4-382 
hydroxyphenylacetic acid, 3,(4-hydroxyphenyl)lactic acid, 3-(4-hydroxyphenyl)pyruvic 383 
acid, L-tyrosine, phenylacetic acid and tyramine increased post-nitisinone; 2-hydroxy-384 
4-(methylthio)butyric acid, 3,5-cyclic AMP, HGA and xanthosine decreased post-385 
nitisinone. The concordance between human and mouse data supports the approach 386 
and validity of the data. For mice, it was possible to control potentially confounding 387 
factors that could affect metabolism, such as diet and genetic diversity. This increases 388 
likelihood that observed changes are attributable to nitisinone. Reduced phenotypic 389 
variation could explain the prominent gender difference observed for mouse only; 390 
histamine was particularly elevated in urine from females, as previously reported in 391 
the literature for rats (40,41) but not mice to our knowledge. 392 
The limitations of this study are as follows. First is the relatively small sample size for 393 
a clinical metabolomics study (25 patients). However, AKU is a rare disease and the 394 
repeated-measures design enhanced statistical power. Second, data represent 395 
changes observed in urine not serum, which more closely reflects internal 396 
homeostasis. The urine metabolome is a composite of products from endogenous 397 
metabolism, diet, drugs and the gut microbiome. Urine does however give a valuable 398 
indication of the metabolic fate of the increased circulating tyrosine post-nitisinone. 399 
Further metabolomic analyses on fluids and tissues from other biological locations are 400 
required to achieve more detailed, compartment-specific data, for example 401 
cerebrospinal fluid to directly study the impact of nitisinone-induced tyrosinaemia on 402 
the central nervous system. Third, three chromatographic methods were used, 403 
however this may not always be feasible. For large-scale studies, it may be pragmatic 404 
to use two of the methods to reduce analytical and processing time. 405 
20 
In conclusion, we have developed a targeted LC-QTOF-MS strategy for 406 
comprehensive coverage of the metabolome with compound structure identification 407 
using three AMRT databases, which are publicly available. Application of the approach 408 
to AKU has advanced our knowledge of the wider metabolic consequences of 409 
nitisinone, demonstrating the potential of our method as a metabolic phenotyping 410 
strategy more generally. 411 
412 
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Table 1. Number of accurate mass retention time (AMRT) matches obtained by the three methods and retained following quality 543 
control filtering and decreasing AMRT window size during feature extraction. 544 
RT, retention time; Positive, positive ionization mode; Negative, negative ionization mode.545 
Feature extraction 
window 
Filtering step Number of urine AMRT matches 
    Method 1    Method 2    Method 3    
    Positive Negative Positive Negative Positive Negative 
 
Accurate mass 10 ppm,                  
RT 0.3 min 
None 274 153 248 105 111 74 
  
 
(1) Unique AMRT's only, 
manual curation 




(2) Abundance QC: peak 
area CV <25% between 
replicates 




(3) RT shift QC: RT CV 
<25% between replicates  
 
75 36 107 35 59 30 
 
Accurate mass 5 ppm, 
RT 0.15 min 
 
Steps (1) - (3) 44 31 65 25 38 22 
 
Accurate mass 2.5 ppm,                 
RT 0.075 min 
 
Steps (1) - (3) 17 21 22 12 14 13 
27 
Figure Legends 546 
Figure 1. Tyrosine catabolic pathway with reference to its defect in alkaptonuria 547 
and treatment with nitisinone. Lack of the enzyme homogentisate 1,2-dioxygenase 548 
increases concentrations of circulating homogentisic acid by preventing its conversion 549 
to maleylacetoacetic acid. It is previously established that nitisinone has the upstream 550 
consequence of increased concentrations of tyrosine, 3-(4-hydroxyphenyl)pyruvic acid 551 
and 3-(4-hydroxyphenyl)lactic acid as a result of the metabolic block induced by 552 
nitisinone. 553 
Figure 2. Summary of the data acquired from analysis of metabolite standards. 554 
A, Venn diagram summarizing the number of compounds retained and detected by 555 
methods 1-3, both alone (non-overlapping sections) and in combination (overlapping 556 
sections). B-D, Mass/RT scatter plots for metabolite standards detected with the three 557 
analytical methods, showing the different selectivities of the methods for compounds 558 
from different chemical classes. 559 
Figure 3. Summary of compounds identified from analysis of urine by accurate 560 
mass retention time (ARMT). A, Venn diagram summarizing the number of AMRT 561 
matches obtained for methods 1-3. B-D, Mass/RT scatter plots for AMRT compound 562 
matches obtained from analysis of urine by the three analytical methods.  563 
Figure 4. Application of the profiling strategy to alkaptonuria (AKU). A, Urine was 564 
obtained from patients with AKU and HGD-/- mice pre- then post-nitisinone therapy. B, 565 
Representative urine profiles (top) and extracted signals (bottom) for compounds 566 
identified by accurate mass retention time. C, Principle component analysis showing 567 
alteration to human (left) and mouse (right) urine metabolomes post-nitisinone. x, y 568 
and z axes represent components 1, 2 and 3 respectively. 569 
28 
Figure 5. Urinary metabolite changes identified post-nitisinone in alkaptonuria 570 
by application of the profiling strategy. Red and blue indicate increases and 571 
decreases respectively. Fold changes (FC’s) are indicated in brackets and were 572 
calculated from raw peak area.  573 
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